FluMistÃ‚® (Influenza Vaccine Live, Intranasal) Begins Shipping for 2011-2012 Influenza Season
GAITHERSBURG, Md., July 18, 2011 /PRNewswire/ -- MedImmune announced today that it has begun shipping FluMist® (Influenza Vaccine Live, Intranasal) to influenza vaccine distributors who service health care providers throughout the United States.
MedImmune expects to provide approximately 15 –16 million doses of its trivalent (three-strain) nasal spray flu vaccine for the 2011-2012 influenza season through a variety of private health care practices, public health departments, school-located vaccination programs, military bases, and other venues. Healthcare professionals should refer to FluMist prescribing information for appropriate administration.
FluMist is indicated for eligible individuals 2-49 years of age. The most common side effects of FluMist are runny or stuffy nose; sore throat and fever over 100 degrees F.
This year, flu vaccines contain the three strains recommended by the Centers for Disease Control and Prevention (CDC), the U.S. Food and Drug Administration (FDA), and World Health Organization (WHO), including the 2009 H1N1 pandemic strain.
The CDC recommends that flu vaccine be administered to eligible recipients aged six months and older every year as soon as the vaccine becomes available. A MedImmune analysis looking at pediatric populations suggests that starting influenza vaccinations as soon as product is available (July – September) — months earlier than the typical influenza vaccination season — may help reach an additional 10.5 million children at already-scheduled healthcare provider visits.
"MedImmune is committed to supporting public health efforts to initiate seasonal influenza vaccination as early as possible each year, greatly widening the window of opportunity for vaccination," said Steve Projan, Ph.D, MedImmune's Senior Vice President, Research & Development. "The data show that vaccination with FluMist in the late summer helps protect against influ